Julius Clinical

What Julius Clinical does

Julius Clinical is a Netherlands-headquartered, science-led Contract Research Organization (CRO) founded in 2008 as a spin-off from the University Medical Center Utrecht. The company provides Phase I-IV clinical trial services, real-world evidence (RWE) and epidemiology studies, and electronic medical record (EMR) data integration for pharmaceutical, biotechnology, and public health clients. It is therapeutically specialized in three core areas: neurological diseases (Alzheimer's, ALS, dementia, hearing loss, pain, seizures), cardio-metabolic and renal diseases (chronic kidney disease, dyslipidemia, MASH/NASH, type 2 diabetes, cardiovascular outcomes trials), and infectious diseases and vaccines (RSV, vaccine development, post-licensure safety studies). The company is majority-owned by Ampersand Capital Partners following a November 2023 investment and operates a "triangle" model combining scientific leadership, global site networks spanning 25+ countries, and operational delivery.

The business operates on a professional services revenue model with quote-based, project-negotiated pricing across three engagement tiers: full-service, functional-service (FSP), and single-service. The go-to-market is enterprise field sales targeting large pharmaceutical companies, mid-sized biotech innovators, and public health institutions, supported by scientific thought leadership including peer-reviewed publications, webinars, industry conferences, and case studies. Following the May 2025 merger with Peachtree BioResearch Solutions (CNS-focused US CRO) and the November 2025 merger with P95 (epidemiology and vaccine specialist), the combined organization comprises over 500 professionals operating across five continents, having executed 400+ clinical trials enrolling 300,000+ subjects. The platform incorporates AI and natural language processing (NLP) for EMR/EHR-based patient eligibility screening, external control arm construction, and feasibility analysis, though AI is a workflow enabler rather than a standalone product offering.

Name

Julius Clinical

Legal name

Julius Clinical Research B.V.

Website

https://juliusclinical.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

101–250 employees

Short description

Julius Clinical is a science-led, therapeutically specialized CRO providing Phase I-IV clinical trials, real-world evidence, and epidemiology services to pharmaceutical, biotech, and public health clients, with core focus on neurological, cardio-metabolic, and infectious disease programs across 25+ countries.

Ownership category

akta.pro rank

Product category

Clinical Research Services (CRO)

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Clinical research services
• Contract research organization
• Real-world evidence
• Clinical trial management
• Therapeutic area expertise

Headquarters

HQ city

Zeist

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Trial Services: Full-service, functional-service, and single-service clinical research organization (CRO) services for pharmaceutical, biotech, and medical device companies. Services span Phase I-IV clinical trials, epidemiology studies, and real-world evidence projects.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Julius Clinical is a science-led Contract Research Organization (CRO) that delivers Phase I-III clinical trials, epidemiology studies, and real-world evidence programs for pharmaceutical, biotech, and public health clients across three core therapeutic areas: neurological diseases, cardio-metabolic and renal diseases, and infectious diseases and vaccines. The company combines scientific leadership, global site networks, and operational delivery through full-service, functional-service, and single-service engagement models, supported by AI/NLP-enabled EMR data integration. Post-merger with P95 in November 2025, the combined organization operates across more than 25 countries with over 500 professionals.

Product overview

Julius Clinical is a science-led Contract Research Organization (CRO) offering integrated clinical development and real-world evidence solutions through a unique triangle model combining scientific leadership, site networks, and delivery excellence. The portfolio spans three core therapeutic areas: Neurological diseases (including Alzheimer's, ALS, dementia), Cardio-Metabolic and Renal diseases (including MASH, diabetes, CKD), and Infectious Diseases & Vaccines. Following the 2025 merger with P95 and Peachtree BioResearch Solutions, the company now operates as a global full-service CRO with flexible engagement models (full-service, functional-service, and single-service) across 25+ countries. Key service offerings include Phase I-III clinical trials, epidemiology and RWE studies, and EMR/EHR data integration using AI/NLP capabilities for patient eligibility and external control arms.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Development Services

Quantifiable outcome

• 23% lower risk of death from any cause with high-dose hemodiafiltration vs hemodialysis (CONVINCE trial published in NEJM)
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• P95coreStrategic or Co-development Partner · 19 November 2025P95 merged with Julius Clinical to form a global, science-led CRO with integrated expertise in neuroscience, cardio-renal-metabolic, and infectious diseases/vaccines. P95 brings leadership in epidemiology, RWE, and vaccine development, with 300 staff across 30 countries.
• Peachtree BioResearch SolutionscoreStrategic or Co-development Partner · 14 May 2025Peachtree BioResearch Solutions, a specialized CNS CRO based in Georgia, USA, merged with Julius Clinical to create a fully integrated global CRO with increased CNS capabilities. The merger combines extensive expertise in managing Phase I-III clinical studies with particular depth in CNS, cardio-metabolic, renal, and rare diseases.
• GRIPonMASH ConsortiumcoreStrategic or Co-development PartnerEuropean research consortium of 27 institutions focused on early detection and understanding of MASLD/MASH. Julius Clinical co-founded the consortium and leads Work Package 2 for screening studies. The 26-million-euro project is funded by IHI JU and includes academic institutions and industry partners.
• Leiden University Medical CenterminorStrategic or Co-development PartnerCollaborated on the AwareNASH survey project to explore healthcare workers' knowledge, practices, and attitudes toward NAFLD/NASH diagnosis and management across 88 countries.
• ReSViNETminorGTM or Marketing PartnerPartner organization for RSV-related webinars including 'RSV and Asthma' and 'Progress in RSV Vaccines and Monoclonal Antibodies'.
• EsperionminorStrategic or Co-development PartnerCollaboration on analysis of CLEAR trial outcomes investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular complications.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Medpace Holdings: Mid-sized specialty CRO with a similar full-service, therapeutically focused operating model serving small-to-mid biotech and large pharma; highly relevant comparable given overlapping therapeutic depth and similar enterprise positioning.
• Worldwide Clinical Trials: Specialty CRO with deep CNS and cardiometabolic expertise offering full-service and functional-service models; directly comparable therapeutic focus and mid-sized private-company profile.
• TFS HealthScience: Specialty CRO focused on CNS, dermatology, ophthalmology and oncology with flexible engagement models; the new CEO Bassem Saleh was formerly CEO here, making it a closely comparable operating model.
• Premier Research: Specialty CRO with therapeutic depth in CNS, oncology and rare disease serving small-to-mid biotech; comparable mid-sized private CRO profile and therapeutic overlap.

Broad incumbents

• ICON plc: One of the largest global CROs offering full-service clinical development across all therapeutic areas; competes head-to-head with Julius Clinical for large pharma CNS and cardio-metabolic trials but with materially greater scale.
• IQVIA: Largest global CRO with integrated R&D services, real-world evidence, and technology platforms; competes across all of Julius Clinical's therapeutic areas with substantially broader operational footprint.
• Parexel International: Large full-service CRO with deep CNS, oncology, and rare disease capabilities; comparable therapeutic focus but materially larger scale and broader geographic coverage.
• Syneos Health: Full-service biopharmaceutical solutions provider offering clinical development and commercialization services; broader scope than Julius Clinical but overlaps in CNS and cardio-metabolic trial execution.
• Charles River Laboratories: Broad life sciences services organization with CRO capabilities in early-stage and clinical research; competes in CNS and rare disease trials with a wider services portfolio spanning discovery through clinical.

Emerging players

• Ergomed: Specialty CRO with focus on oncology and rare disease that was acquired by IQVIA in 2024; historically comparable mid-sized specialty CRO model now operating within the IQVIA platform.

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/juliusclinical
• Facebookfacebook.com/sharer/sharer.php?u=https://www.juliusclinical.com
• LinkedInlinkedin.com/company/julius-clinical

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Julius Clinical